Supplements challenger Heights has raised a further £2m to support its rapid growth and boost stock inventory as the business pushes to keep up with consumer demand.
The latest round values the company at £57.8m, a significant jump from the £33m level hit during the previous £2m raise in 2024.
Co-founded by Joel Freeman and Dan Murray in 2020, Heights sells a range of supplements DTC on its website, including the flagship Vitals all-in-one multivitamin, which is designed to support sleep, reduce fatigue, and target brain, heart and bone health, as well as assisting the immune system.
The brand has recently surpassed £20m in annual recurring revenues and expects to record its one millionth order by the end of this year. Heights said the business doubled in size this year and aimed to do the same in 2026, with ambitions to take sales to £50m.
Heights will use the latest investment for NPD, growing stock and more clinical research into its product range.
Murray said: “Having doubled the business in 2025, we’re thrilled to have closed a £2m round in just one week. It will help us double down on our core focus of science research and evidence, working towards our goal of becoming Europe’s most trusted supplement brand.
“Our aim is to raise the standards of this industry that’s lost the trust and respect of consumers and bring rigour and scientific credibility to it with the best products in the market that are proven to work. This raise helps us invest in more trials to do just that.”
Heights has now raised just more than £9m across five funding rounds. The latest raise came from existing investors, such as New Look founder Tom Singh, WeTransfer founder Damian Bradfield and Deciem founder Nicola Kilner, as well as a top-up from the crowd.
No comments yet